Insider · CIK 0001865119
Laura Stoppel
director
Files at ABOS (Acumen Pharmaceuticals, Inc.), ARTV (Artiva Biotherapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | ARTV Artiva Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +16,250 | $0.00 | $0 | 16,250 | 28 d ago |
| Sep 8, 2026 | ARTV Artiva Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +13,750 | $0.00 | $0 | 13,750 | 34 d ago |
| Jun 24, 2025 | ARTV Artiva Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +13,750 | $0.00 | $0 | 13,750 | Jun 26, 2025 |
| Jun 4, 2025 | ABOS Acumen Pharmaceuticals, Inc. | AGrant or award Common Stock | +12,800 | $0.00 | $0 | 12,800 | Jun 5, 2025 |
| Jun 4, 2025 | ABOS Acumen Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +19,500 | $0.00 | $0 | 19,500 | Jun 5, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.